Weight-loss patients voice concerns as CVS Caremark drops Zepbound coverage for Wegovy, though exceptions may exist for those ...

Thousands find weight loss relief on Zepbound. Now, they face a choice: Try a different medicine that may have adverse side effects or stop treatment.

We recently published 10 Stocks That Jim Cramer Talked About. CVS Health Corporation (NYSE:CVS) is one of the stocks Jim ...

Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) fell 4.3% in the morning session after its key competitor in the ...

Some patients reluctantly shifted to save money while others have appealed for coverage of Zepbound after having experienced ...

Starting July 1, CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from ...

We recently published 10 Stocks That Jim Cramer Talked About. Eli Lilly and Company (NYSE:LLY) is one of the stocks Jim ...

Novo Nordisk A/S's Wegovy, a semiglutide injectable medicine, is now the primary weight loss drug offered on CVS's standard formulary, a list of medications an insurance plan covers. The news was not ...

Pharmacy benefit manager CVS Caremark drops Zepbound coverage, estimating 10-15% savings while Eli Lilly offers self-pay ...

Eli Lilly on Thursday downplayed CVS Health’s decision to drop the company’s obesity drug Zepbound from some lists of medicines it covers for reimbursement, but shares of the drugmaker still ...

CVS Health selected former Eli Lilly CFO Derica Rice to serve as the president of its pharmacy benefit management division, CVS Caremark, according to The Wall Street Journal. Effective March 30 ...

Goldman Sachs cuts Eli Lilly's price target to $883, citing PBM-related uncertainty after CVS dropped Zepbound. BofA keeps $1,000 price target, saying Zepbound remains superior and CVS move is not ...